(OCUP) – Management Comments
-
Ocuphire Pharma (OCUP) to Present Data and Updates on APX3330 and Nyxol
-
Ocuphire Pharma (OCUP) Reports Complete Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol for Reversal of Mydriasis
-
-
Back to OCUP Stock Lookup